Vol 6 Issue 3

CELL AND GENE THERAPY INSIGHTS

April 2020 Issue

Vol 6 Issue 3

Download PDF

Featuring

Issue Spotlight: Viral vector bioprocessing & analytics: tools and innovations to meet future demand
Other articles
Webinars

SPOTLIGHT

Viral vector bioprocessing & analytics: tools and innovations to meet future demand
Nolan Sutherland
Guest Editor:
Nolan Sutherland, Senior Scientist at Ring Therapeutics

Expert Insight

Lentiviral vector manufacturing process enhancement utilizing TFDF™ technology

Lentiviral vector manufacturing process enhancement utilizing TFDF™ technology

T Williams, O Goodyear, L Davies et al.
5 May 2020
Read

Innovator Insight

Development and validation of quantitative real-time PCR for the detection of residual HEK-293 host cell DNA

Development and validation of quantitative real-time PCR for the detection of residual HEK-293 host cell DNA

Kara Norman
28 April 2020
Read
A reproducible, high-throughput platform to quantitatively study AAVs

A reproducible, high-throughput platform to quantitatively study AAVs

James White, Natalia Rodionova
28 April 2020
Read

Interview

Scaling AAV vector manufacture: overcoming roadblocks to the translation of gene therapies

Scaling AAV vector manufacture: overcoming roadblocks to the translation of gene therapies

Nicole Faust
14 May 2020
Read
Vector production in academia: obstacles and opportunities

Vector production in academia: obstacles and opportunities

Daniela Bischof, Emily Hopewell
5 May 2020
Read
Drawing parallels and cross-pollinating ideas between viral vector and vaccine fields

Drawing parallels and cross-pollinating ideas between viral vector and vaccine fields

Amine Kamen
5 May 2020
Read
What is ‘quality’ in viral vector manufacture? Strengths and limitations of current analytical tools

What is ‘quality’ in viral vector manufacture? Strengths and limitations of current analytical tools

Markus Hörer
4 May 2020
Read
How are fixed-bed bioreactors set to change viral vector processing?

How are fixed-bed bioreactors set to change viral vector processing?

Pim Velthof, Pranav Puri, Jolanda Van Vliet
28 April 2020
Read
Are suspension-based systems for cell and gene therapy key to commercial-scale manufacture?

Are suspension-based systems for cell and gene therapy key to commercial-scale manufacture?

Patrick Erbacher
27 April 2020
Read

Journal articles

Research Article

Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain

Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain

Adriana Lopes , Rob Noel, Andrew Sinclair
2 June 2020
Read

Innovator Insight

Key steps to industrialize your process and de-risk your pathway to commercialization

Key steps to industrialize your process and de-risk your pathway to commercialization

Behnam Baghbaderani
4 May 2020
Read
Addressing the current limitations of AAV gene therapies

Addressing the current limitations of AAV gene therapies

Dmitry A Kuzmin, Natalie R Johnston
1 May 2020
Read

Commentary

Trends in cell and gene therapy clinical development for rare and ultra-rare diseases

Trends in cell and gene therapy clinical development for rare and ultra-rare diseases

Sven Kili
29 April 2020
Read

Interview

Cell therapy’s role in defeating Covid-19

Cell therapy’s role in defeating Covid-19

Yaky Yanay
18 May 2020
Read
Venture creation for cell and gene therapy and beyond

Venture creation for cell and gene therapy and beyond

Bruce Booth
4 April 2020
Read

Commercial Insights

Cell & Gene Therapy Commercial Insight – February 2020

Cell & Gene Therapy Commercial Insight – February 2020

Mark Curtis, Richard Philipson
19 March 2020
Read

Webinars